


Synthesis and Characterization of Oligodeoxyribonucleotides Modified with 2'-Amino- α -L-LNA Adenine Monomers: High-Affinity Targeting of Single-Stranded DNA

Nicolai K. Andersen,^{†,§} Brooke A. Anderson,^{‡,§} Jesper Wengel,[†] and Patrick J. Hrdlicka^{‡,*}

[†]Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, 5230 Odense, Denmark

[‡]Department of Chemistry, University of Idaho, Moscow, Idaho 83844-2343, United States

Supporting Information



ABSTRACT: The development of conformationally restricted nucleotide building blocks continues to attract considerable interest because of their successful use within antisense, antigene, and other gene-targeting strategies. Locked nucleic acid (LNA) and its diastereomer α -L-LNA are two interesting examples thereof. Oligonucleotides modified with these units display greatly increased affinity toward nucleic acid targets, improved binding specificity, and enhanced enzymatic stability relative to unmodified strands. Here we present the synthesis and biophysical characterization of oligodeoxyribonucleotides (ONs) modified with 2'-amino- α -L-LNA adenine monomers W–Z. The synthesis of the target phosphoramidites 1–4 is initiated from pentafuranose 5, which upon Vorbrüggen glycosylation, O2'-deacylation, O2'-activation and C2'-azide introduction yields nucleoside 8. A one-pot tandem Staudinger/intramolecular nucleophilic substitution converts 8 into 2'-amino- α -L-LNA adenine intermediate 9, which after a series of nontrivial protecting-group manipulations affords key intermediate 15. Subsequent chemoselective N2'-functionalization and O3'-phosphitylation give targets 1–4 in ~1–3% overall yield over 11 steps from 5. ONs modified with pyrene-functionalized 2'-amino- α -L-LNA adenine monomers X–Z display greatly increased affinity toward DNA targets (ΔT_m /modification up to +14 °C). Results from absorption and fluorescence spectroscopy suggest that the duplex stabilization is a result of pyrene intercalation. These characteristics render N2'-pyrene-functionalized 2'-amino- α -L-LNAs of considerable interest for DNA-targeting applications.

INTRODUCTION

Major efforts have been devoted over the past 20 years to the development of conformationally restricted nucleotides. Oligonucleotides that are modified with these building blocks often display markedly increased affinity toward nucleic acid targets, improved discrimination of nontargets, and greater resistance against enzymatic degradation relative to reference strands.¹ Such oligonucleotides are accordingly widely used for nucleic acid-targeting applications in molecular biology, biotechnology, and medicinal chemistry.² Locked nucleic acid (LNA) is one of the most prominent members of this compound class because of its extraordinary affinity toward DNA and RNA complements (Figure 1); thus, increases in the thermal denaturation temperature (T_m) of up to +10 °C per modification have been observed.^{3–5} The diastereomeric α -L-LNA (Figure 1) shares many characteristics with LNA,

including very high affinity toward DNA/RNA targets, but is less well characterized as a result of its more limited commercial availability.⁶ The interesting properties of LNA, α -L-LNA, and other conformationally restricted nucleotides have spurred the development of many analogues.^{1,7}

As part of our ongoing interest in LNA chemistry and diagnostic applications of pyrene-functionalized oligonucleotides,^{2c,8} we recently pursued the development of N2'-pyrene-functionalized 2'-amino- α -L-LNA thymine monomers (Figure 1).⁹ Oligodeoxyribonucleotides (ONs) modified with these monomers display remarkable affinity toward complementary DNA, as the pyrene moieties are preorganized to intercalate and engage in stacking with neighboring nucleobases upon

Received: October 13, 2013

Published: December 4, 2013





Figure 1. Structures of LNA, α -L-LNA, and the 2'-amino- α -L-LNA monomers studied herein. T = thymine-1-yl.

Scheme 1. Retrosynthetic Analysis of 2'-Amino- α -L-LNA-adenine Monomers W–Z^a



^aAbbreviations: PG = PN(*i*Pr)₂OCH₂CH₂CN; R = H, CH₂Py, COPy, and COCH₂Py for W–Z, respectively; py = pyren-1-yl; A^{Bz} = 6-*N*-benzoyladenine-9-yl.


duplex formation.^{9b} Thus, increases in T_m of up to 20 °C per modification have been observed for short ONs modified with these building blocks. We have taken advantage of these characteristics and have developed probes for a variety of diagnostic applications. For example, ONs modified with two next-nearest-neighbor incorporations of 2'-*N*-(pyren-1-yl)-acetyl-2'-amino- α -L-LNA-T monomers are promising tools for the detection of single-nucleotide polymorphisms, which are the most prevalent type of genetic mutation in the human genome.¹⁰ These probes efficiently discriminate between complementary and single-base-mismatched DNA/RNA targets through differences in pyrene excimer emission levels. In another example, the fluorescence of ONs modified with 2'-*N*-(pyren-1-yl)acetyl-2'-amino- α -L-LNA-T monomers was found to increase 16-fold upon hybridization with DNA targets featuring abasic sites (i.e., DNA lesions that result in genomic mutations and emergence of cancers if unrepaired).¹¹ We have also utilized N2'-pyrene-functionalized 2'-amino- α -L-LNA-T monomers as the key activating components of the so-called Invader probes, which recognize mixed-sequence double-stranded DNA.¹² Unfortunately, the synthesis of N2'-pyrene-functionalized 2'-amino- α -L-LNA-thymine phosphoramidites is challenging (~20 steps, <4% overall yield from diacetone- α -D-glucose), mainly because of unsuccessful attempts to introduce the necessary C2'-azido group at the nucleoside level without concomitant O2,O2'-anhydronucleoside formation.^{9a} This

forced us to introduce the azido group at the carbohydrate level, which resulted in a loss of anchimeric assistance from the O2-position during Vorbrüggen glycosylation and the formation of anomeric nucleoside mixtures. We hypothesized that these synthetic difficulties might be overcome with the corresponding adenine derivatives, as the formation of anhydronucleosides would be unlikely. Easier access to N2'-pyrene-functionalized 2'-amino- α -L-LNA monomers is desirable in order to evaluate the diagnostic potential of these building blocks in greater detail.


In the present article, we report the synthesis and characterization of ONs modified with four different 2'-amino- α -L-LNA-adenine monomers W–Z (Figure 1). The ONs were characterized via thermal denaturation, UV–vis, and fluorescence experiments and shown to display extraordinary thermal affinity toward complementary DNA (ΔT_m /modification up to 14.0 °C) and photophysical characteristics consistent with intercalative binding modes for the pyrene moieties.¹³

RESULTS AND DISCUSSION

Retrosynthetic Analysis of 2'-Amino- α -L-LNA-A Monomers. Inspired by our previously reported synthesis of the corresponding thymine monomers,⁹ we identified adenine derivative 15 as a suitable substrate for chemoselective N2'-functionalization and subsequent O3'-phosphitylation, which were expected to yield the target 6-*N*-benzoyladenine-9-yl

Scheme 2. Synthesis of Intermediate 9^a

^aAbbreviations: BSA = *N,O*-bis(trimethylsilyl)acetamide; 1,2-DCE = 1,2-dichloroethane; A^{Bz} = 6-*N*-benzoyladenine-9-yl; GNO₃ = guanidinium nitrate; 15-C-5: 15-crown-5.

Scheme 3. Synthesis of Key Intermediate 15^a

^aAbbreviations: A^{Bz} = 6-*N*-benzoyladenine-9-yl; DMTr = 4,4'-dimethoxytrityl; FmocCl = 9'-fluorenylmethyl chloroformate.

nucleosides 1–4 (Scheme 1). We surmised that key intermediate 15 could be obtained from nucleoside 9 via a series of protecting-group manipulations. The O3'-benzyl group was selected because of (i) its stability under acidic and basic reaction conditions, allowing it to be introduced at the beginning of the synthetic route, and (ii) its ability to be removed under conditions that have only a minimal effect on the 6-*N*-benzoyl group of adenine.¹⁴ We expected to construct the 2-oxo-5-azabicyclo[2.2.1]heptane skeleton of 9 in a manner similar to that originally reported for 2'-amino-β-D-LNA,¹⁵ namely, via a one-pot tandem Staudinger/intramolecular nucleophilic substitution reaction, which revealed nucleoside 8 as an early target. In contrast to our synthesis of the corresponding thymine monomer, where the C2'-azido group had to be introduced at the carbohydrate stage,^{9a} we decided to introduce the 2'-azido group of 8 at the nucleoside stage, anticipating that selective O2'-deacylation of known nucleoside

6^b and subsequent O2'-activation and introduction of the azido group would provide 8. Importantly, the anchimeric assistance provided by the O2-substituent during the Vorbrüggen glycosylation of 5 to give 6 prevents formation of anomeric mixtures, which is one of the drawbacks in the synthesis of 2'-amino-α-L-LNA-T monomers.^{9a}

Synthesis of Key Intermediate 15. Fully protected pentafuranose 5, which was obtained from diacetone-α-D-glucose in six steps and ~30% overall yield,^{6b,16} served as the starting material for the synthesis of key intermediate 15 (Scheme 2). Glycosyl donor 5 was converted into alcohol 7 following protocols that deviated from the known route^{6b} in the following manner: (i) the use of trimethylsilyl triflate as the Lewis acid and 1,2-dichloroethane as the reaction solvent during Vorbrüggen glycosylation of 5 afforded 6 in higher yield and with easier workup than the original protocol involving tin(IV) chloride and acetonitrile (70% vs 57%, respectively);

(ii) the use of the guanidinium nitrate/sodium methoxide reagent mixture¹⁷ resulted in slightly more efficient O2'-deacylation of **6** than the original protocol employing dilute methanolic ammonia (88% vs 79% yield), although the dilute reaction conditions of the former approach rendered it less practical for large-scale reactions. Alcohol **7** was O2'-triflated and treated with sodium azide and 15-crown-5 in DMF at elevated temperatures to furnish azide **8** in excellent yield (89% over two steps). IR spectra of **8** verified the presence of the azide group (sharp band at 2115 cm⁻¹). Nucleoside **8** was converted into the desired 2'-amino- α -L-LNA intermediate **9** via a one-pot tandem Staudinger/intramolecular nucleophilic substitution reaction using alkaline trimethylphosphine¹⁵ in a satisfying 85% yield.¹⁸ The 2-oxo-5-azabicyclo[2.2.1]heptane skeleton and stereochemical configuration of **9** were verified by NOE difference experiments on downstream products (vide infra).

The protecting-group manipulations needed to convert nucleoside **9** into key intermediate **15** proved to be surprisingly challenging (Scheme 3). For example, O3'-debenzylation of bicyclic nucleoside **9** was unsuccessful using boron trichloride or methanesulfonic acid in dichloromethane. Similarly, the corresponding N2'-Fmoc-protected nucleoside **10** (obtained by reacting **9** with 9'-fluorenylmethyl chloroformate under Schotten–Baumann conditions; results not shown) failed to undergo O3'-debenzylation with BCl₃ in dichloromethane or by standard hydrogenolysis. Additional attempted strategies are outlined in Scheme S1 in the Supporting Information. Therefore, it proved necessary to protect the N2'-position of bicyclic nucleoside **9** as a trifluoroacetamide to give nucleoside **11** in 62% yield, which was then O3'-debenzylated with BCl₃ in hexanes to give nucleoside **12** in 87% yield (Scheme 3). Protection of the O3'-position as a naphthyl ether would be an attractive alternative option, as it can be cleaved using DDQ,^{7a} but this option was not considered at the time of the synthesis. Subsequent nucleophilic substitution of the C5'-mesylate group of **12** was attempted using potassium acetate and 18-crown-6, but this resulted in the formation of numerous side products according to analytical TLC, and the approach was abandoned (Scheme 3). Instead, treatment of **12** with sodium benzoate and 15-crown-5 in hot DMF afforded O5'-benzoylated nucleoside **13** in 83% yield. Subsequent treatment of nucleoside **13** with aqueous sodium hydroxide in 1,4-dioxane effected the cleavage of both the O5'-benzoyl and N2'-trifluoroacetamide protecting groups, affording polar amino alcohol **14** in 60% yield after column chromatography. The O5'-hydroxyl group of nucleoside **14** was subsequently protected as the 4,4'-dimethoxytrityl (DMTr) ether using standard conditions to afford key intermediate **15**. Curiously, the reaction proceeded in no more than 38% yield, as significant amounts of N2',O5'-di-DMTr-protected nucleoside **16** were produced as well (30% yield). Efforts to optimize the yield of **15** (e.g., slow addition of DMTr-Cl at low temperatures) were unsuccessful. However, it was possible to recycle nucleoside **16** into amino diol **14** using 3% dichloroacetic acid in a mixture of methanol and nitromethane¹⁹ in up to 96% yield. An alternative strategy toward **15**, involving N2'-Fmoc protection of **14** and subsequent O5'-DMTr-protection and N2'-Fmoc deprotection, was dismissed because O5'-DMTr protection was inefficient (~40% yield; results not shown). Thus, the preferred route (**5** → **9** → **11** → **15**) afforded intermediate **15** in ~5% overall yield from **5**, not taking the recycling step **16** → **14** into account.

Structural Verification of the 2'-Amino- α -L-LNA Configuration. In agreement with previously reported ¹H NMR signals of other α -L-LNA nucleosides,^{6b,9} the ¹H NMR signals of H1', H2', and H3' of 2'-amino- α -L-LNA nucleosides appear as singlets or narrow doublets ($J < 2$ Hz)²⁰ since the H1'–C1'–C2'–H2' and H2'–C2'–C3'–H3' torsion angles are fixed in *+gauche* and *-gauche* conformations, respectively. The structure of bicyclic nucleoside **14** was ascertained by NOE difference spectroscopy. NOE contacts between H1' and H2' (7%), H1' and H3' (5%), and H2' and H3' (2%) suggested a *cis* relationship between these protons (Figure 2). Since the





Figure 2. Key NOE contacts in nucleoside **14**.

stereochemical configuration at C3' is defined by the choice of starting material and remains unchanged throughout synthesis, H1' and H2' must be pointing “down”, which confirms the nucleobase as pointing “up” and hence establishes the 2'-amino- α -L-LNA configuration. This was substantiated by signal enhancements between H5'_A and H8' (6%), indicating a *cis* relationship between the nucleobase and H5'' (H5'_A is tentatively assigned as the H5'' closest to the nucleobase).

Synthesis of Phosphoramidite Building Blocks 1–4. Chemoselective N2'-functionalizations of key intermediate **15** to give nucleosides **17**–**20** were realized as follows: (i) using 9'-fluorenylmethyl chloroformate to give **17** in 51% yield (Schotten–Baumann conditions could not be used because of the low solubility of **15** in dioxane/water); (ii) via reductive amination using 1-pyrenecarboxaldehyde and sodium triacetoxyborohydride²¹ as the reducing agent to give **18** in 68% yield; or (iii) via EDC-mediated coupling of 1-pyrenecarboxylic acid or 1-pyreneacetic acid to give **19** in 64% yield and **20** in 79% yield, respectively (Scheme 4). Subsequent phosphitylation using 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite afforded the target compounds **1**–**4** in 46–71% yield after column chromatography and precipitation.

Synthesis of Modified ONs and Experimental Design. Phosphoramidites **1**–**4** were used in machine-assisted solid-phase DNA synthesis (0.2 μ mol scale) to incorporate monomers W–Z into ONs using the following hand-coupling conditions (activator; coupling time; stepwise coupling yield): monomer W (pyridinium hydrochloride; 30 min; ~82%); monomers X–Z (pyridinium hydrochloride; 15 min; ~95%). Following workup and HPLC purification, the composition and purity of all of the modified ONs were ascertained by MALDI MS analysis (Tables S1 and S2 in the Supporting Information) and ion-pair reversed-phase HPLC, respectively. ONs containing a single incorporation in the 5'-GTG BTA TGC context are denoted W1, X1, Y1, and Z1, respectively. Similar conventions apply for ONs in the B2–B6 series (see Table 1). Reference DNA and RNA strands are denoted as D1/D2 and R1/R2, respectively. The following descriptive nomenclature is also

Scheme 4. Synthesis of Phosphoramidites 1–4^a

^aAbbreviations: A^{Bz} = 6-*N*-benzoyladenine-9-yl; DIPEA = *N,N'*-diisopropylethylamine; DMTr = 4,4'-dimethoxytrityl; EDC·HCl = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; FmocCl = 9'-fluorenylmethyl chloroformate; NMI = *N*-methylimidazole; PCI = 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite; Py = pyren-1-yl.

used: N2'-PyMe (**X** series), N2'-PyCO (**Y** series) and N2'-PyAc (**Z** series). We previously used this 9-mer mixed-sequence context to study the hybridization properties of ONs modified with N2'-pyrene-functionalized 2'-amino- α -L-LNA-thymine monomers, which facilitates a direct comparison.⁹

Thermal Denaturation Experiments. Thermal Affinity toward Complementary DNA/RNA. The thermostabilities of duplexes between W/X/Y/Z-modified ONs and complementary DNA/RNA were evaluated by determining their thermal denaturation temperatures (T_m) in medium-salt buffer ($[\text{Na}^+] = 110 \text{ mM}$, pH 7.0). The changes in T_m for the modified duplexes relative to the T_m values for the unmodified reference duplexes (ΔT_m) are discussed.

ONs with one or two incorporations of 2'-amino- α -L-LNA-adenine monomer **W** display very similar thermal affinities toward complementary DNA as the unmodified reference ONs (ΔT_m between -1.0 to $+0.5$ °C; Table 1). Thus, unlike the corresponding 2'-oxy- α -L-LNA-adenine monomer,^{6b,22} the 2-oxo-5-azabicyclo[2.2.1]heptane skeleton of monomer **W** is not inherently beneficial for DNA duplex formation. We have made similar observations with ONs modified with the thymine counterpart of monomer **W**.^{9a} This indicates that the unfunctionalized 2'-nitrogen of 2'-amino- α -L-LNA monomers either stabilizes the single-stranded ON or destabilizes the duplex, for example, by perturbing the hydration spine in the major groove. In contrast, ONs modified with N2'-pyrene-functionalized 2'-amino- α -L-LNA-adenine monomer **X**, **Y**, or **Z** display greatly increased thermal affinity toward DNA targets (ΔT_m /modification between $+2.5$ and $+14$ °C; Table 1). The observed T_m trends for singly modified ONs ($Y > Z \geq X$)

Table 1. ΔT_m Values for Duplexes between B1–B6 and Complementary DNA Targets^a

ON	duplex	ΔT_m /°C			
		B = W	B = X	B = Y	B = Z
B1	5'-GTG B TA TGC				
D2	3'-CAC TAT ACG	-0.5	+5.0	+11.0	+6.0
B2	5'-GTG AT B TGC				
D2	3'-CAC TAT ACG	+0.5	+7.0	+14.0	+7.5
B3	5'-GTG B T B TGC				
D2	3'-CAC TAT ACG	-1.0	+5.0	+13.5	+16.0
D1	5'-GTG ATA TGC				
B4	3'-CAC T B T ACG	± 0.0	+6.5	+11.5	+7.5
D1	5'-GTG ATA TGC				
B5	3'-CAC TAT B CG	± 0.0	+5.5	+12.0	+6.0
D1	5'-GTG ATA TGC				
B6	3'-CAC T B T B CG	-2.0	+5.0	+13.5	+14.5

^a ΔT_m = change in T_m relative to the value for the unmodified reference duplex **D1:D2** ($T_m \equiv 27.5$ °C). T_m was determined as the maximum of the first derivative of the melting curve (A_{260} vs T) recorded in medium-salt buffer ($[\text{Na}^+] = 110 \text{ mM}$, $[\text{Cl}^-] = 100 \text{ mM}$, pH 7.0 ($\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$)) using a concentration of $1.0 \mu\text{M}$ for each strand. T_m values are averages of at least two measurements within 1.0 °C. A/C/G/T = adenine-9-yl/cytosine-1-yl/guanine-9-yl/thymine-1-yl DNA monomers. For the structures of monomers **W–Z**, see Figure 1. Data for the **B1**, **B2**, **B4**, and **B5** series for monomers **X**, **Y**, and **Z** were previously reported in ref 12b.

indicate that (i) monomers in which the pyrene moiety is attached to the 2-oxo-5-azabicyclo[2.2.1]heptane skeleton via an alkanoyl linker induce greater thermostabilization than the corresponding monomers employing alkyl linkers (N2'-PyCO

Y > N2'-PyMe X) and (ii) monomers with short alkanoyl linkers result in more thermostable DNA duplexes than the corresponding monomers with longer alkanoyl linkers (N2'-PyCO Y > N2'-PyAc Z). We previously observed similar structure–property relationships with the analogous thymine monomers, which on the basis of UV–vis spectroscopy and molecular modeling results were explained by differential placement of the pyrene moiety for affinity-enhancing intercalation.^{9b} Similar structural underpinnings are likely in effect for monomers X–Z (vide infra). However, the electron density of the pyrene moieties, which differs among the three monomers, may also be a contributing factor to the differential duplex stabilization.

An interesting trend was observed for the doubly modified ONs: incorporation of a second N2'-PyMe X or N2'-PyCO Y monomer did not result in additionally increased thermal affinity against DNA targets, whereas a second incorporation of the more flexible N2'-PyAc Z monomer did (compare the ΔT_m values for the B1–B3 and B4–B6 series in Table 1). We hypothesize that the former observation is due to violation of the “nearest-neighbor exclusion principle”, which states that free intercalators at most bind to every second base pair of a DNA duplex because of limits on the local expandability of duplexes.²³ If the principle is extrapolated to tethered intercalators and 3'-intercalative binding modes of the pyrene moieties of monomers X–Z are assumed (vide infra), the resulting duplexes involving B3 and B6 would feature a localized region with two intercalators in an area defined by four base pairs, which is at the saturation threshold. We speculate that the greater flexibility of the N2'-PyAc Z monomer allows the modified DNA duplexes to structurally compensate for any stress induced by the high intercalator density.

Interestingly, the modified ONs displayed rather different thermal denaturation characteristics with RNA targets. ONs modified with 2'-amino- α -L-LNA adenine monomer W displayed significantly higher affinity against RNA than DNA targets (ΔT_m /modification between +1.5 and +7.0 °C; Table 2). Further, X- and Y-modified ONs displayed markedly lower thermal affinities toward RNA than DNA targets, with N2'-PyMe X-modified DNA:RNA duplexes displaying similar thermostabilities as unmodified reference duplexes (ΔT_m /modification between –0.5 and +2.5 °C; Table 2) and N2'-

Table 2. ΔT_m Values for Duplexes between B1–B6 and Complementary RNA Targets^a

ON	duplex	ΔT_m /°C			
		B = W	B = X	B = Y	B = Z
B1	5'-GTG B TA TGC				
R2	3'-CAC UAU ACG	+2.5	–1.0	+1.5	+4.0
B2	5'-GTG AT B TGC				
R2	3'-CAC UAU ACG	+2.5	+1.0	+5.0	+4.5
B3	5'-GTG B T B TGC				
R2	3'-CAC UAU ACG	+3.0	–1.5	+4.5	+11.0
R1	5'-GUG AUA UGC				
B4	3'-CAC T B T ACG	+4.5	–0.5	+2.5	+6.5
R1	5'-GUG AUA UGC				
B5	3'-CAC TAT B CG	+7.0	+2.5	+6.5	+8.0
R1	5'-GUG AUA UGC				
B6	3'-CAC T B T B CG	+7.0	±0.0	+7.0	+14.5

^a ΔT_m = change in T_m relative to the value for the unmodified reference duplex D1:R2 ($T_m \equiv 26.0$ °C) or R1:D2 ($T_m \equiv 24.5$ °C); for conditions of the thermal denaturation experiments, see Table 1.

PyCO Y-modified duplexes being moderately stabilized (ΔT_m /modification between +1.5 and +6.5 °C; Table 2). N2'-PyAc Z-modified ONs also displayed lower affinities toward RNA than DNA targets but resulted in more thermostable heteroduplexes (ΔT_m /modification between +4.0 and +8.0 °C; Table 2). These differences may again reflect the greater flexibility of monomer Z, which allows the pyrene moieties to adopt more favorable positions for affinity-enhancing intercalation (vide infra). DNA-selective hybridization (Table S3 in the Supporting Information), as seen for X/Y/Z-modified ONs and ONs modified with the thymine counterparts,^{9b} is often observed for ONs modified with intercalating moieties,²⁴ as intercalators favor the B-type helix geometry of DNA:DNA duplexes over the more compressed A/B-type helix geometry of DNA:RNA duplexes.²⁵

Mismatch Discrimination. The binding specificities of centrally modified ONs against DNA/RNA strands with mismatched nucleotides opposite the W–Z monomers were determined. W4 displayed improved discrimination of mismatched DNA targets relative to reference strand D2, with the AG mismatch being discriminated particularly well (Table 3).

Table 3. Discrimination of Mismatched DNA Targets by B4 Series and Reference ONs^a

ON	sequence	DNA: 5'-GTG A BA TGC			
		T_m /°C		ΔT_m /°C	
		B = T	B = A	B = C	B = G
D2	3'-CAC TAT ACG	27.5	–17.0	–15.5	–9.0
W4	3'-CAC T W T ACG	27.5	–20.0	–17.0	–16.0
X4	3'-CAC T X T ACG	34.0	–16.5	–7.5	–17.0
Y4	3'-CAC T Y T ACG	39.0	–21.0	–12.0	–17.0
Z4	3'-CAC T Z T ACG	35.0	–21.5	–14.0	–14.5

^aFor conditions of the thermal denaturation experiments, see Table 1. T_m values for the fully matched duplexes are shown in bold. ΔT_m = change in T_m relative to the value for the fully matched DNA:DNA duplex.

X4/Y4/Z4 displayed surprisingly efficient discrimination of mismatched DNA targets, particularly of AG mismatches (Table 3), considering the likely intercalative binding mode of the pyrene moieties, which is known to typically decrease base-pairing fidelity.^{9b,26} However, ONs with X/Y/Z monomers positioned as next-nearest neighbors displayed poor discrimination of the centrally mismatched DNA target (B3 series; Table S4 in the Supporting Information), indicating that the modification pattern has a major influence on the binding specificity. Discrimination of RNA mismatches was generally less efficient with W4/X4/Y4 than with reference ONs but improved with Z4 (Table 4).

Optical Spectroscopy. UV–vis absorption and steady-state fluorescence emission spectra of X/Y/Z-modified ONs and the corresponding duplexes with DNA/RNA targets were recorded to gain additional insight into the binding modes of the pyrene moieties of monomers X/Y/Z. Bathochromic shifts of pyrene absorption maxima, which are indicative of strong interactions between pyrenes and nucleobases,²⁷ were generally observed upon hybridization with complementary DNA/RNA ($\Delta\lambda_{\max} = 0$ –6 nm; Table 5, Figure 3, and Figures S2 and S3 in the Supporting Information), with the most pronounced increases being observed for duplex formation of Y-modified ONs with DNA. These results are consistent with intercalative binding modes for the pyrene moieties of monomers X/Y/Z

Table 4. Discrimination of Mismatched RNA Targets by B4 Series and Reference ONs^a

ON	sequence	RNA: 5'-GUG <u>ABA</u> UGC			
		$T_m/^\circ\text{C}$		$\Delta T_m/^\circ\text{C}$	
		<u>B</u> = U	<u>B</u> = A	<u>B</u> = C	<u>B</u> = G
D2	3'-CAC TAT ACG	24.5	-15.0	-15.0	-11.0
W4	3'-CAC <u>T</u> TT ACG	29.0	-13.5	-13.0	-11.5
X4	3'-CAC <u>T</u> <u>X</u> T ACG	24.0	-10.5	-8.0	-10.0
Y4	3'-CAC <u>T</u> <u>Y</u> T ACG	27.0	-10.5	-11.0	-8.5
Z4	3'-CAC <u>T</u> <u>Z</u> T ACG	31.0	-19.0	-15.5	-14.5

^aFor conditions of the thermal denaturation experiments, see Table 1. T_m values for the fully matched duplexes are shown in bold. ΔT_m = change in T_m relative to the value for the fully matched RNA:DNA duplex.

and in agreement with our previous observations for the corresponding thymine analogues.^{9b}

Steady-state fluorescence emission spectra were recorded at 5 °C using an excitation wavelength of $\lambda_{\text{ex}} = 350$ nm. Hybridization of N2'-PyMe X-modified or N2'-PyAc Z-modified ONs with complementary DNA/RNA resulted in decreased emission (Figure 3 and Figures S4 and S7 in the Supporting Information), which is consistent with intercalation-induced quenching by flanking nucleobases.^{27,28} The resulting duplexes were only weakly fluorescent and exhibited defined vibronic bands at ~380 nm and ~400 nm along with a shoulder at 420–425 nm. On the other hand, a range of responses was observed upon hybridization of N2'-PyCO Y-modified ONs with complementary DNA/RNA, varying from ~50% reduction to ~3-fold enhancement of emission (Figure S5 in the Supporting Information). The resulting duplexes were strongly fluorescent (nearly 2 orders of magnitude more fluorescent than X-modified duplexes) with little or no vibronic fine structure ($\lambda_{\text{em,max}} \approx 400$ nm, broad band). The lack of a consistent response upon hybridization to DNA/RNA presumably is not due to different pyrene binding modes in the resulting duplexes but rather reflects different fluorescence intensities of the single-stranded probes, possibly due to different sequence-dependent rotational barriers around the Py–CO bond. Thus, singly modified DNA duplexes displayed similar emission intensities (Figure S6 in the Supporting Information), suggesting that the pyrene moieties are in similar microenvironments in the duplex, which is consistent with an intercalative binding mode.

To further substantiate the proposed intercalative binding mode of N2'-PyCO monomer Y, we synthesized three additional Y-modified ONs in which the 3'-flanking nucleotide was varied systematically (Y7–Y9, Table 6). ONs with 3'-flanking purines displayed greater relative increases in thermal affinity against DNA targets than the corresponding ONs with 3'-flanking pyrimidines (compare the ΔT_m values for Y7:D3 and Y9:D5 with those for Y8:D4 and Y4:D1 in Table 6). This is consistent with the proposed binding mode, as 3'-intercalating pyrenes are expected to interact more strongly with large purines.

Steady-state fluorescence emission experiments provided further evidence for an intercalative binding mode of the pyrenes, as the emission levels of these four DNA duplexes decreased in the anticipated order of nucleobase quenching efficiency (from least to most quenched: 3'-flanking A > T > C > G; Figure 4).^{28b,29}

CONCLUSION

ONs modified with N2'-pyrene-functionalized 2'-amino- α -L-LNA-adenine monomers X–Z display very high affinity toward DNA targets. The DNA-selective hybridization, together with hybridization-induced bathochromic shifts of pyrene absorption maxima and quenching of pyrene fluorescence, is indicative of intercalative binding modes for the pyrene moieties. ONs with such characteristics are likely to be of significant interest for applications in nucleic acid diagnostics and biotechnology.³⁰ However, the synthesis of the corresponding phosphoramidites is very challenging because of nontrivial protecting-group manipulations (<1% overall yield from diacetone- α -D-glucose), which emphasizes the need for a more efficient synthetic route toward these building blocks or access to functional analogues of N2'-functionalized 2'-amino- α -L-LNA monomers, which are easier to synthesize. In fact, we have already discovered the first examples of such analogues, namely, N2'-pyrene-functionalized 2'-N-methyl-2'-amino-DNA and O2'-pyrene-functionalized RNA monomers,^{8a,12b} and are exploring their use for applications in nucleic acid diagnostics.^{8b,c}

EXPERIMENTAL SECTION

9-[2-O-Acetyl-3-O-benzyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl- α -L-threo-pentofuranosyl]-6-N-benzoyladenine (6). 6-N-Benzoyladenine (28.6 g, 0.12 mol) and glycosyl donor **5^{6b}** (40.6 g, 79.8 mmol) were coevaporated with 1,2-dichloroethane (2 × 150 mL) and resuspended in anhydrous 1,2-dichloroethane (270 mL). To this was added N,O-bis(trimethylsilyl)-

Table 5. Absorption Maxima in the 300–400 nm Region for ONs Modified with N2'-Pyrene-Functionalized 2'-Amino- α -L-LNA Adenine Monomers X/Y/Z in the Presence or Absence of Complementary DNA/RNA Targets^a

ON	sequence	$\lambda_{\text{max}}/\text{nm}$ [$\Delta\lambda_{\text{max}}/\text{nm}$]								
		<u>B</u> = X			<u>B</u> = Y			<u>B</u> = Z		
		SSP	+DNA	+RNA	SSP	+DNA	+RNA	SSP	+DNA	+RNA
B1	5'-GTG <u>B</u> TA TGC	348	350 [+2]	350 [+2]	349	352 [+3]	351 [+2]	348	350 [+2]	351 [+3]
B2	5'-GTG <u>A</u> TB TGC	348	350 [+2]	349 [+1]	349	353 [+4]	351 [+2]	350	351 [+1]	351 [+1]
B3	5'-GTG <u>B</u> TB TGC	347	349 [+2]	348 [+1]	349	351 [+2]	351 [+2]	347	350 [+3]	351 [+4]
B4	3'-CAC <u>T</u> BT ACG	348	350 [+2]	348 [\pm 0]	347	353 [+6]	352 [+5]	348	351 [+3]	351 [+3]
B5	3'-CAC TAT <u>B</u> CG	348	350 [+2]	350 [+2]	350	351 [+1]	350 [\pm 0]	348	351 [+3]	351 [+3]
B6	3'-CAC <u>T</u> BT <u>B</u> CG	348	350 [+2]	348 [\pm 0]	348	352 [+4]	353 [+5]	348	351 [+3]	351 [+3]

^a $\Delta\lambda_{\text{max}}$ = change in absorption maximum relative to λ_{max} for the single-stranded probe (SSP). Measurements were performed at 5 °C except for the single-stranded X/Y-modified probes, whose spectra were recorded at room temperature. Buffer conditions were the same as in the thermal denaturation experiments.




Figure 3. (left) UV–vis absorption and (right) steady-state fluorescence emission spectra of **Z4** in the presence or absence of complementary DNA/RNA. $T_{\text{exp}} = 5\text{ }^{\circ}\text{C}$; each ON was used at $1\text{ }\mu\text{M}$ concentration in T_m buffer; $\lambda_{\text{ex}} = 350\text{ nm}$ (fluorescence).

Table 6. T_m Values for Duplexes between **Y4/Y7/Y8/Y9** and Complementary DNA Targets^a

ON	duplex	$\Delta T_m/^{\circ}\text{C}$	reference $T_m/^{\circ}\text{C}$
D3	5'–GTG TT ATGC	+17.0	27.5
Y7	3'–CAC AY TACG		
D4	5'–GTG GT ATGC	+10.0	33.0
Y8	3'–CAC CY TACG		
D5	5'–GTG CT ATGC	+19.5	24.0 ^b
Y9	3'–CAC GY TACG		
D1	5'–GTG AT ATGC	+11.5	27.5
Y4	3'–CAC TY TACG		

^a ΔT_m = change in T_m relative to the value for the unmodified reference duplex. For experimental conditions, see Table 1. ^bThe low T_m of this reference duplex was confirmed by two independent operators using strands from three different commercial batches.




Figure 4. Fluorescence emission spectra of duplexes between **Y4/Y7/Y8/Y9** and complementary DNA targets. The nucleotide flanking the **Y** monomer on its 3'–side is listed in the parentheses. $T_{\text{exp}} = 5\text{ }^{\circ}\text{C}$; each ON used at $0.15\text{ }\mu\text{M}$ concentration in T_m buffer; $\lambda_{\text{ex}} = 350\text{ nm}$.

acetamide (BSA) (49.2 mL, 0.20 mol), and the suspension was heated at reflux until it turned homogeneous. The solution was then cooled to rt. TMSOTf (43.1 mL, 0.24 mol) was slowly added, and the reaction mixture was heated at reflux for 70 h. The mixture was then cooled to rt and slowly poured into a solution of sat. aq. NaHCO_3 and crushed ice (500 mL, 1:1 v/v). Additional crushed ice (~400 mL) was added, and the mixture was stirred for 30 min. The resulting precipitate was removed via filtration, and the filtrate was extracted with CH_2Cl_2 (1.5 L). The organic layer was washed with sat. aq. NaHCO_3 ($2 \times 500\text{ mL}$), and the combined aqueous layer was back-extracted with CH_2Cl_2 ($2 \times 500\text{ mL}$). The combined organic layer was evaporated to afford a

crude residue, which was purified by silica gel column chromatography (0–10% v/v *i*-PrOH in CH_2Cl_2) to provide nucleoside **6** (38.3 g, 70%) as a white foam. $R_f = 0.4$ (5% v/v MeOH in CH_2Cl_2); MALDI-HRMS m/z 712.1380 ($[\text{M} + \text{Na}]^+$, $\text{C}_{29}\text{H}_{31}\text{N}_5\text{O}_{11}\text{S}_2\cdot\text{Na}^+$, calcd 712.1354). The observed ^{13}C NMR data (75.5 MHz, CDCl_3) are in good agreement with previously reported data for this compound.^{6b}

9-[3-O-Benzyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl- α -L-threo-pentofuranosyl]-6-N-benzoyladenine (7). Fully protected nucleoside **6** (4.66 g, 6.76 mmol) was dissolved in a solution¹⁷ of guanidinium nitrate (4.91 g, 40.2 mmol) and NaOMe (0.24 g, 4.44 mmol) in MeOH: CH_2Cl_2 (450 mL, 9:1 v/v). The reaction mixture was stirred at rt for 30 min, at which point sat. aq. NH_4Cl (200 mL) was added. The resulting white precipitate was filtered off and washed with CH_2Cl_2 , and the filtrate was concentrated. The aqueous layer was extracted with CH_2Cl_2 ($5 \times 200\text{ mL}$), and the combined organic layers were evaporated to near dryness. The resulting crude residue was purified by silica gel column chromatography (0–4% v/v MeOH in CH_2Cl_2) to afford alcohol **7** (3.84 g, 88%) as a white foam. $R_f = 0.5$ (10% v/v MeOH in CH_2Cl_2); MALDI-HRMS m/z 670.1234 ($[\text{M} + \text{Na}]^+$, $\text{C}_{27}\text{H}_{29}\text{N}_5\text{O}_{10}\text{S}_2\cdot\text{Na}^+$, calcd 670.1248). The observed ^{13}C NMR data (75.5 MHz, CDCl_3) are in good agreement with previously reported data for this compound.^{6b}

9-[2-C-Azido-3-O-benzyl-2-deoxy-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl- α -L-erythro-pentofuranosyl]-6-N-benzoyladenine (8). Alcohol **7** (18.6 g, 28.7 mmol) was coevaporated with anhydrous pyridine (50 mL) and dissolved in anhydrous CH_2Cl_2 (200 mL). The solution was cooled to $-78\text{ }^{\circ}\text{C}$, and anhydrous pyridine (7.3 mL, 90.6 mmol) was added, followed by dropwise addition of trifluoromethanesulfonyl anhydride (Trf_2O) (9.90 mL, 58.9 mmol). The reaction mixture was allowed to warm to rt and stirred for 3 h. At this point, crushed ice (50 mL) was added, and the layers were separated. The organic layer was washed with sat. aq. NaHCO_3 ($2 \times 50\text{ mL}$), evaporated to near dryness, and coevaporated with abs. EtOH ($2 \times 50\text{ mL}$) to afford the crude O2'-triflate as a light-brown residue, which was used in the next step without further purification.

NaN_3 (19.6 g, 0.30 mol) and 15-crown-5 (6.0 mL, 0.30 mol) were added to a solution of the crude O2'-triflate in anhydrous DMF (300 mL). The reaction mixture was stirred first at rt for 15 h and then for an additional 8 h at $50\text{ }^{\circ}\text{C}$. After the mixture was cooled to rt, the solids were filtered off and washed with EtOAc, and the combined organic layers were concentrated until near dryness. The concentrate was taken up in EtOAc (200 mL) and brine (200 mL), and the layers were separated, after which the aqueous layer extracted with EtOAc ($4 \times 100\text{ mL}$). The combined organic layers were evaporated to near dryness, and the resulting crude residue was purified by silica gel column chromatography (0–90% v/v EtOAc in petroleum ether) to afford azide **8** (17.9 g, 89% over two steps) as a white solid material. $R_f = 0.4$ (EtOAc); IR (KBr) 2116 cm^{-1} (N_3); MALDI-HRMS m/z 695.1295 ($[\text{M} + \text{Na}]^+$, $\text{C}_{27}\text{H}_{28}\text{N}_8\text{O}_9\text{S}_2\cdot\text{Na}^+$, calcd 695.1313); ^1H NMR

(300 MHz, DMSO-*d*₆) δ 11.30 (s, 1H, ex), 8.79 (s, 1H), 8.54 (s, 1H), 8.05 (d, 2H, *J* = 7.0 Hz), 7.30–7.67 (m, 8H), 6.74 (d, 1H, *J* = 4.4 Hz), 5.08–5.16 (m, 1H), 4.89 (d, 1H, *J* = 5.1 Hz), 4.74–4.83 (m, 2H), 4.69–4.72 (d, 1H, *J* = 11.4 Hz), 4.47–4.51 (d, 1H, *J* = 11.4 Hz), 4.42 (s, 2H), 3.28 (s, 3H), 3.24 (s, 3H); ¹³C NMR (75.5 MHz, DMSO-*d*₆) δ 151.9, 150.4, 142.7, 136.9, 133.2, 132.5, 128.5, 128.0, 81.9, 81.7, 80.1, 73.5, 68.3, 61.9, 36.98, 36.94. The carbonyl group of the 6-*N*-benzoyl group was not visible.

(1S,3R,4S,7R)-3-(6-*N*-Benzoyladenine-9-yl)-7-benzoyloxy-1-methanesulfonyloxymethyl-2-oxa-5-azabicyclo[2.2.1]heptane (9). Aqueous NaOH (2 M, 38.9 mL, 77.8 mmol) and trimethylphosphine (1 M in THF, 77.8 mL, 77.8 mmol) were added to an ice-cold solution of azido nucleoside 8 (35.2 g, 51.8 mmol) in THF (500 mL). The reaction mixture was allowed to warm to rt and was stirred at this temperature for 21 h. The mixture was then evaporated to near dryness, and the resulting crude residue taken up in EtOAc (200 mL) and brine (200 mL). After the layers were separated, the aqueous layer was extracted with MeOH:CH₂Cl₂ (3 × 200 mL, 2:8 v/v). The combined organic layers were evaporated to dryness, and the resulting crude material was purified by silica gel column chromatography (0–5% v/v MeOH in CH₂Cl₂) to provide bicyclic nucleoside 9 (24.2 g, 85%) as a solid brown material. *R*_f = 0.3 (EtOAc); MALDI-HRMS *m/z* 573.1517 ([M + Na]⁺, C₂₆H₂₆N₆O₆S·Na⁺, calcd 573.1527); ¹H NMR^{31,32} (500 MHz, DMSO-*d*₆) δ 11.17 (s, 1H, ex, NH), 8.77 (s, 1H, H8), 8.73 (s, 1H, H2), 8.06 (d, 2H, *J* = 7.0 Hz, Bz), 7.54–7.67 (m, 3H, Bz), 7.29–7.47 (m, 5H, Ph), 6.52 (d, 1H, *J* = 1.8 Hz, H1'), 4.72–4.76 (d, 1H, *J* = 11.7 Hz, CH₂Ph), 4.62–4.67 (d, 1H, *J* = 11.7 Hz, CH₂Ph), 4.57–4.60 (d, 1H, *J* = 11.7 Hz, H5'_A), 4.49–4.53 (d, 1H, *J* = 11.7 Hz, H5'_B), 4.45 (s, 1H, H3'), 3.93 (br s, 1H, H2'), 3.28–3.31 (m, 1H, H5'_A, partial overlap with H₂O), 3.22 (s, 3H, CH₃SO₂), 3.10–3.13 (d, 1H, *J* = 9.9 Hz, H5''_B); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.5, 152.1, 151.4 (C2), 150.0, 143.1 (C8), 137.8, 133.3, 132.3 (Bz), 128.4 (Ar), 128.2 (Ar), 127.62 (Ar), 127.60 (Ar), 125.1, 87.2, 84.3 (C1'), 80.4 (C3'), 71.0 (CH₂Ph), 66.8 (C5'), 59.8 (C2'), 51.1 (C5''), 36.8 (CH₃SO₂). The ¹H and ¹³C NMR data are in reasonable agreement with previously reported data from the patent literature.¹⁸ The 2-oxo-5-azabicyclo[2.2.1]heptane skeleton and stereochemistry of 9 were verified via NOE experiments on downstream product 14.

(1S,3R,4S,7R)-3-(6-*N*-Benzoyladenine-9-yl)-7-benzoyloxy-1-methanesulfonyloxymethyl-5-trifluoroacetyl-2-oxa-5-azabicyclo[2.2.1]heptane (11). Bicyclic nucleoside 9 (8.68 g, 15.8 mmol) was coevaporated with pyridine (2 × 20 mL) and dissolved in anhydrous CH₂Cl₂ (200 mL) and anhydrous pyridine (5.09 mL, 63 mmol). The solution was cooled to 0 °C, and trifluoroacetic acid anhydride (4.45 mL, 31.5 mmol) was added. The reaction mixture was stirred for 2 h at 0 °C, at which point crushed ice (50 mL) was added. The layers were separated, and the organic layer was washed with sat. aq. NaHCO₃ (2 × 50 mL). The combined aqueous layers were back-extracted with CH₂Cl₂ (2 × 100 mL) and MeOH:CH₂Cl₂ (100 mL, 2:8 v/v), and the combined organic layers were evaporated to near dryness. The resulting crude residue was sequentially coevaporated with toluene (50 mL) and abs. EtOH:toluene (50 mL, 1:1 v/v) and purified by silica gel column chromatography (0–100% v/v EtOAc in petroleum ether) to afford fully protected nucleoside 11 (6.27 g, 62%) as a white foam. *R*_f = 0.5 (10% v/v MeOH:EtOAc). Physical data for the mixture of rotamers (~4:6 by ¹H NMR): MALDI-HRMS *m/z* 647.1541 ([M + H]⁺, C₂₈H₂₅F₃N₆O₆S·H⁺, calcd 647.1530); ¹H NMR^{31,32} (500 MHz, DMSO-*d*₆) δ 11.21 (br s, 1H, ex, NH_{A+B}), 8.59 (s, 0.45H, H8_A), 8.78 (s, 0.6H, H2_B), 8.76 (s, 0.4H, H2_A), 8.63 (s, 0.4H, H8_A), 8.60 (s, 0.6H, H8_B), 8.05 (d, 2H, *J* = 7.0 Hz, Bz_{A+B}), 7.52–7.67 (m, 3H, Bz_{A+B}), 7.31–7.41 (m, 5H, Ph_{A/B}), 6.83 (d, 0.6H, *J* = 1.1 Hz, H1'_B), 6.80 (d, 0.4H, *J* = 1.1 Hz, H1'_A), 5.26 (s, 0.4H, H2'_A), 5.17 (s, 0.6H, H2'_B), 4.84 (s, 0.6H, H3'_B), 4.82 (s, 0.4H, H3'_A), 4.62–4.79 (m, 4H, CH₂Ph_{A+B}, H5'_{A+B}), 4.53 (d, 0.4H, *J* = 10.6 Hz, H5''_A), 4.35 (d, 0.6H, *J* = 12.1 Hz, H5''_B), 4.07 (d, 0.4H, *J* = 10.6 Hz, H5''_A), 3.91 (d, 0.6H, *J* = 12.1 Hz, H5''_B), 3.28 (s, 3H, CH₃SO₂); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.49, 165.48, 155.3 (q, *J* = 37 Hz, COCF₃), 155.0 (q, *J* = 37 Hz, COCF₃), 151.8 (C2_B), 151.65 (C2_A), 151.59, 150.4, 150.3, 141.2 (C8_B), 141.0 (C8_A), 137.2, 137.0, 133.3, 132.4 (Bz), 128.43 (Bz), 128.40 (Ar), 128.39 (Ar), 128.38 (Ar),

128.34 (Ph), 127.91 (Ph), 127.88 (Ph), 127.53 (Ph), 127.51 (Ph), 125.5, 125.3, 115.5 (q, *J* = 288 Hz, CF₃), 115.2 (q, *J* = 288 Hz, CF₃), 86.16, 86.15, 84.9 (C1'_A), 84.0 (C1'_B), 79.2 (C3'_B), 77.4 (C3'_A), 71.6 (CH₂Ph), 65.3 (C5'), 65.0 (C5'), 63.0 (C2'_B), 61.4 (C2'_A), 53.2 (C5''_B), 53.1 (C5''_A), 37.0 (CH₃SO₂); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -71.3 (CF_{3,B}), -72.1 (CF_{3,A}).

(1S,3R,4S,7R)-3-(6-*N*-Benzoyladenine-9-yl)-7-hydroxy-1-methanesulfonyloxymethyl-5-trifluoroacetyl-2-oxa-5-azabicyclo[2.2.1]heptane (12). Fully protected nucleoside 11 (19.6 g, 30.4 mmol) was coevaporated with 1,2-dichloroethane (3 × 100 mL) and dissolved in anhydrous CH₂Cl₂ (600 mL). The solution was cooled to -78 °C, and BCl₃ (1 M solution in hexanes, 370 mL, 0.37 mol) was added. The reaction mixture was allowed to warm to rt and was stirred for 17 h. The mixture was then cooled to 0 °C, and crushed ice (800 mL) was slowly added. The layers were separated, and the organic phase was washed with sat. aq. NaHCO₃ (2 × 300 mL). The combined aqueous layers were back-extracted with EtOAc (4 × 500 mL), and the combined organic phases were evaporated to near dryness. The resulting residue was purified using silica gel column chromatography (0–20% v/v MeOH in CH₂Cl₂) to afford alcohol 12 (14.7 g, 87%) as a white solid material. *R*_f = 0.3 (50% v/v acetone in CH₂Cl₂). Physical data for the mixture of rotamers (~4:6 by ¹H NMR): MALDI-HRMS *m/z* 579.0871 ([M + Na]⁺, C₂₁H₁₉F₃N₆O₇S·Na⁺, calcd 579.0880); ¹H NMR^{31,32} (500 MHz, DMSO-*d*₆) δ 11.21 (s, 1H, ex, NH_{A+B}), 8.76 (s, 0.6H, H2_B), 8.75 (s, 0.4H, H2_A), 8.60 (s, 0.4H, H8_A), 8.56 (s, 0.6H, H8_B), 8.04 (d, 2H, *J* = 7.7 Hz, Bz_{A+B}), 7.48–7.66 (m, 3H, Bz_{A+B}), 6.83 (d, 0.6H, *J* = 1.4 Hz, H1'_B), 6.80 (d, 0.4H, *J* = 1.4 Hz, H1'_A), 6.72 (d, 0.6H, ex, *J* = 4.1 Hz, 3'-OH_B), 6.68 (d, 0.4H, ex, *J* = 4.1 Hz, 3'-OH_A), 4.91 (br s, 0.4H, H2'_A), 4.82 (d, 0.6H, *J* = 4.1 Hz, H3'_B), 4.76 (d, 0.4H, *J* = 4.1 Hz, H3'_A), 4.70 (br s, 0.6H, H2'_B), 4.60–4.67 (m, 2H, H5'_{A+B}), 4.46 (d, 0.4H, *J* = 10.3 Hz, H5''_A), 4.26 (d, 0.6H, *J* = 11.7 Hz, H5''_B), 4.03 (d, 0.6H, *J* = 10.3 Hz, H5''_A), 3.86 (d, 0.5H, *J* = 11.7 Hz, H5''_B), 3.29 (s, 3H, CH₃SO₂); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.5, 155.3 (q, *J* = 36.6 Hz, COCF₃), 155.1 (q, *J* = 36.6 Hz, COCF₃), 151.7 (C2_{A/B}), 151.6 (C2_{A/B}), 150.3, 150.2, 141.2 (C8_B), 141.0 (C8_A), 132.4 (Bz), 128.44 (Bz), 128.42 (Bz), 128.39 (Bz), 128.38 (Bz), 125.5, 125.3, 115.5 (q, *J* = 288 Hz, CF₃), 115.2 (q, *J* = 288 Hz, CF₃), 87.0, 85.8, 84.8 (C1'_A), 83.9 (C1'_B), 72.5 (C3'_B), 70.7 (C3'_A), 65.7 (C5'), 65.4 (C5'), 65.3 (C2'_B), 63.7 (C2'_A), 52.8 (C5''_B), 52.6 (C5''_A), 37.0 (CH₃SO₂); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -71.1 (CF_{3,B}), -72.1 (CF_{3,A}).

(1S,3R,4S,7R)-3-(6-*N*-Benzoyladenine-9-yl)-1-benzoyloxy-methyl-7-hydroxy-5-trifluoroacetyl-2-oxa-5-azabicyclo[2.2.1]heptane (13). NaOBz (2.99 g, 20.8 mmol) and 15-crown-5 (2.07 mL, 10.4 mmol) were added to a solution of alcohol 12 (5.79 g, 10.4 mmol) in anhydrous DMF (100 mL). The reaction mixture was stirred first at 90 °C for 5 h and then at rt for an additional 18 h. The mixture was concentrated to near dryness and taken up in EtOAc and brine. The layers were separated, and the aqueous layer was extracted with EtOAc (4 × 200 mL). The combined organic layers were evaporated to near dryness, and the resulting residue was purified by silica gel column chromatography (0–3.5% v/v *i*-PrOH in CHCl₃) to afford O5'-benzoylated nucleoside 13 (5.05 g, 83%) as a white foam. *R*_f = 0.4 (10% v/v *i*-PrOH in CHCl₃). Physical data for the mixture of rotamers (~4.5:5.5 by ¹H NMR): MALDI-HRMS *m/z* 605.1337 ([M + Na]⁺, C₂₇H₂₁F₃N₆O₆·Na⁺, calcd 605.1367); ¹H NMR^{31,32} (500 MHz, DMSO-*d*₆) δ 11.21 (br s, 1H, ex, NH_{A+B}), 8.69 (s, 1H, H2_{A+B}), 8.59 (s, 0.45H, H8_A), 8.54 (s, 0.55H, H8_B), 8.05–8.13 (m, 4H, Bz_{A+B}), 7.49–7.72 (m, 6H, Bz_{A+B}), 6.86 (d, 0.55H, *J* = 1.7 Hz, H1'_B), 6.83 (d, 0.45H, *J* = 1.7 Hz, H1'_A), 6.60–6.80 (br s, 1H, ex, 3'-OH_{A+B}), 4.93 (s, 0.55H, H3'_B), 4.89–4.91 (m, 0.9H, H2'_A, H3'_A), 4.74–4.79 (m, 1.0H, H5'_{A+B}), 4.68 (br s, 0.55H, H2'_B), 4.58–4.64 (m, 1.0H, H5'_{A+B}), 4.54 (d, 0.45H, *J* = 10.7 Hz, H5''_A), 4.35 (d, 0.55H, *J* = 11.5 Hz, H5''_B), 4.10 (d, 0.45H, *J* = 10.7 Hz, H5''_A), 3.93 (d, 0.55H, *J* = 11.5 Hz, H5''_B); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 166.5, 165.3, 155.1 (2q, *J* = 36 Hz, COCF₃), 151.8 (C2_{A/B}), 151.6 (C2_{A/B}), 151.4, 140.6 (C8_{A/B}), 140.4 (C8_{A/B}), 134.5, 134.4, 133.6 (Bz), 131.9 (Bz), 129.55 (Bz), 129.54 (Bz), 129.18, 129.17, 128.7 (Bz), 128.4 (Bz), 128.2 (Bz), 125.5, 125.3, 115.5 (2q, CF₃, *J* = 286 MHz, CF₃), 87.4, 86.0, 84.5 (C1'_A), 83.7 (C1'_B), 72.9 (C3'_B), 71.0 (C3'_A), 65.3 (C2'_B), 63.7 (C2'_A), 60.7

(C5'), 60.2 (C5'), 53.0 (C5''_B), 52.9 (C5''_A), minor impurities were observed at δ 121.3, 119.9, and 79.1; ^{19}F NMR (376 MHz, DMSO-*d*₆) δ -71.1 (CF_{3,B}), -72.0 (CF_{3,A}).

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-7-hydroxy-1-hydroxymethyl-2-oxa-5-azabicyclo[2.2.1]heptane (14). From 13: Aqueous NaOH (2 M, 17.5 mL, 0.35 mol) was added to an ice-cold solution of alcohol 13 (3.41 g, 5.85 mmol) in 1,4-dioxane and water (225 mL, 2:1 v/v). The reaction mixture was stirred at 0 °C for 2 h, at which point sat. aq. NH₄Cl (25 mL) was added. The solution was evaporated to dryness, and the resulting crude material was adsorbed on silica gel and purified by silica gel column chromatography (0–20% v/v MeOH in CH₂Cl₂) to afford amino alcohol 14 (1.33 g, 60%) as a white solid material. *R*_f = 0.4 (20% v/v MeOH in CH₂Cl₂); MALDI-HRMS *m/z* 405.1294 ([M + Na]⁺, C₁₈H₁₈N₆O₄·Na⁺, calcd 405.1282); ^1H NMR (300 MHz, DMSO-*d*₆) δ 11.17 (br s, 1H, ex, NH), 8.73 (s, 1H, A^{Bz}), 8.71 (s, 1H, A^{Bz}), 8.05 (d, 2H, *J* = 8.1 Hz, Bz), 7.49–7.67 (m, 3H, Bz), 6.44 (d, 1H, *J* = 1.9 Hz, H1'), 5.70 (d, 1H, ex, *J* = 4.0 Hz, 3'-OH), 4.82 (t, 1H, ex, *J* = 5.5 Hz, 5'-OH), 4.30 (d, 1H, *J* = 4.0 Hz, H3'), 3.69 (d, 2H, *J* = 5.5 Hz, H5'), 3.51 (s, 1H, H2'), 3.15–3.20 (d, 1H, *J* = 10.6 Hz, H5''), 2.94–3.01 (d, 1H, *J* = 10.6 Hz, H5''); ^{13}C NMR (75.5 MHz, DMSO-*d*₆) δ 165.5, 152.0, 151.2, 149.8, 143.2, 133.3, 132.3, 128.4, 125.2, 91.3, 83.9, 73.4, 62.2 (C5''), 58.3 (C2'), 50.6 (C5').

From 16: Nucleoside 16 (1.00 g, 1.01 mmol) was dissolved in CHCl₂COOH/MeOH/CH₃NO₂ (50 mL, 3:5:92 v/v/v), and the solution was stirred at 0 °C for 15 min. Sat. aq. NaHCO₃ was carefully added to neutralize the solution, and the mixture was evaporated to dryness and adsorbed on silica gel. The resulting residue was purified by silica gel column chromatography (0–20% v/v MeOH in CH₂Cl₂, initially built including 1% v/v Et₃N) to afford amino diol 14 as a white solid material (0.37 g, 96%).

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane (15) and **(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-5-(4,4'-dimethoxytrityl)-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane (16).** Amino alcohol 14 (1.25 g, 3.27 mmol) was coevaporated with anhydrous pyridine (30 mL) and redissolved in anhydrous pyridine (65 mL). The solution was cooled using an ice–salt mixture, and DMTrCl (1.55 g, 4.58 mmol) was added in one portion (addition over several portions did not influence reaction outcome). The reaction mixture was warmed to rt and stirred for 23 h, at which point MeOH (10 mL) was added. The mixture was diluted with EtOAc (100 mL) and washed with sat. aq. NaHCO₃ (2 × 15 mL). The combined aqueous layers were back-extracted with EtOAc (3 × 30 mL), and the combined organic phases were evaporated to dryness and subsequently coevaporated with abs. EtOH:toluene (3 × 50 mL, 2:1 v/v). The resulting residue was purified by silica gel column chromatography (0–8% v/v MeOH in CH₂Cl₂, initially built with 0.5% v/v Et₃N) and subsequently coevaporated with abs. EtOH:toluene (2 × 50 mL, 1:1 v/v) to afford nucleoside 15 (0.85 g, 38%) as a white solid material along with nucleoside 16 (0.97 g, 30%) as a yellow foam.

Physical data for 15: *R*_f = 0.4 (10% v/v MeOH in CH₂Cl₂); MALDI-HRMS *m/z* 707.2609 ([M + Na]⁺, C₃₉H₃₆N₆O₆·Na⁺, calcd 707.2589); ^1H NMR³¹ (500 MHz, DMSO-*d*₆) δ 11.16 (br s, 1H, ex, NH), 8.78 (s, 1H, H8), 8.73 (s, 1H, H2), 8.06 (d, 2H, *J* = 7 Hz, Bz), 7.63–7.67 (t, 1H, *J* = 7.7 Hz, Bz), 7.54–7.58 (d, 2H, *J* = 7.0 Hz, Bz), 7.19–7.44 (m, 9H, DMTr), 6.86–6.92 (m, 4H, DMTr), 6.54 (d, 1H, *J* = 1.9 Hz, H1'), 5.66 (d, 1H, ex, *J* = 4.8 Hz, 3'-OH), 4.40 (d, 1H, *J* = 4.8 Hz, H3'), 3.74 (s, 6H, CH₃O), 3.50 (br s, 1H, H2'), 3.30–3.32 (m, 1H, H5'), overlap with H₂O), 3.25–3.27 (d, 1H, *J* = 10.7 Hz, H5'), 3.19 (br s, 2H, H5''), 2.90 (br s, 1H, ex, 2'-NH); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 165.5, 158.0, 152.2, 151.3 (C2), 149.9, 144.8, 143.3 (C8), 135.5, 135.4, 133.4, 132.3 (Ar), 129.71 (Ar), 129.68 (Ar), 128.45, 128.39 (Ar), 127.8 (Ar), 127.7 (Ar), 126.6 (Ar), 125.2, 113.2 (DMTr), 89.6, 85.1, 84.1 (C1'), 74.0 (C3'), 62.2 (C2'), 61.2 (C5'), 55.0 (CH₃O), 51.2 (C5').

Physical data for 16: *R*_f = 0.5 (3% v/v MeOH in CH₂Cl₂); MALDI-HRMS *m/z* 1009.3900 ([M + Na]⁺, C₆₀H₅₄N₆O₈·Na⁺, calcd 1009.3895); ^1H NMR³¹ (500 MHz, DMSO-*d*₆) δ 11.33 (br s, 1H,

ex, NH), 9.13 (s, 1H, H8), 8.77 (s, 1H, H2), 8.10 (d, 2H, *J* = 7.5 Hz, Bz), 7.64–7.67 (t, 1H, *J* = 7.5 Hz, Bz), 7.52–7.58 (t, 2H, *J* = 7.5 Hz, Bz), 6.78–7.41 (m, 22H, DMTr), 6.58 (d, 1H, *J* = 1.1 Hz, H1'), 6.53 (d, 2H, *J* = 9.1 Hz, DMTr), 6.43 (d, 2H, *J* = 9.1 Hz, DMTr), 4.26 (d, 1H, *J* = 5.0 Hz, H3'), 3.82 (d, 1H, *J* = 9.9 Hz, H5''), 3.75 (br s, 1H, H2'), 3.73 (s, 6H, CH₃O), 3.65 (s, 3H, CH₃O), 3.62 (s, 3H, CH₃O), 3.55 (d, 1H, ex, *J* = 5.0 Hz, 3'-OH), 3.17–3.19 (d, 1H, *J* = 11.0 Hz, H5'), 3.09–3.11 (d, 1H, *J* = 11.0 Hz, H5'), 2.98 (d, 1H, *J* = 9.9 Hz, H5''); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 165.7, 158.0, 157.05, 156.96, 152.0, 151.6 (C2), 150.3, 145.2, 144.8, 142.9 (C8), 136.7, 136.2, 136.0, 135.4, 135.3, 133.3, 132.4 (Bz), 130.5 (DMTr), 130.2 (DMTr), 129.8 (DMTr), 129.7 (DMTr), 128.8 (DMTr), 128.44 (Bz), 128.39 (Bz), 127.73 (DMTr), 127.70 (DMTr), 127.1 (DMTr), 126.5 (DMTr), 126.3, 125.5 (DMTr), 123.8 (DMTr), 113.1 (DMTr), 112.5 (DMTr), 112.4 (DMTr), 88.4, 86.6 (C1'), 85.2, 74.3, 74.0 (C3'), 64.3 (C2'), 60.7 (C5'), 55.0 (C5''), 54.9 (CH₃O), 54.8 (CH₃O), 54.75 (CH₃O), 54.73 (CH₃O). A trace impurity of pyridine was identified in the ^{13}C NMR spectrum at δ 149.5.

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-1-(4,4'-dimethoxytrityloxymethyl)-5-(9'-fluorenylmethoxycarbonyl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane (17). Amino alcohol 15 (200 mg, 0.29 mmol) was coevaporated in anhydrous pyridine (2 × 2 mL) and redissolved in anhydrous pyridine (1.5 mL). The solution was cooled to 0 °C, and 9'-fluorenylmethyl chloroformate (100 mg, 0.38 mmol) added thereto. The reaction mixture was warmed to rt and stirred for 6 h, at which point it was diluted with EtOAc (30 mL) and washed with sat. aq. NaHCO₃ (30 mL). The aqueous layer was back-extracted with EtOAc (25 mL), and the combined organic layers were evaporated to near dryness. The resulting crude material was coevaporated with abs. EtOH:toluene (2 × 6 mL, 2:1 v/v) and purified by silica gel column chromatography (30–100% v/v EtOAc in petroleum ether) to afford target nucleoside 17 (136 mg, 51%) as a white foam. *R*_f = 0.4 (EtOAc). Physical data for the mixture of rotamers (~1:1.2 by ^1H NMR): MALDI-HRMS *m/z* 929.3241 ([M + Na]⁺, C₅₄H₄₆N₆O₈·Na⁺, calcd 929.3269); ^1H NMR (300 MHz, DMSO-*d*₆) δ 11.29 (br s, ex), 8.74 (s, 1H), 8.72 (s, 1.2H), 8.55 (s, 1.2H), 8.49 (s, 1H), 6.90–8.08 (m, 57.2H), 6.80 (d, 1.2H, *J* = 1.7 Hz), 6.73 (d, 1H, *J* = 1.7 Hz), 6.25 (d, 1.2H, ex, *J* = 4.4 Hz), 6.22 (d, 1H, ex, *J* = 4.4 Hz), 4.50 (br s, 1.2H), 4.45 (br s, 1H), 4.22 (d, 1H, *J* = 6.9 Hz), 4.15 (d, 1.2H, *J* = 6.9 Hz), 3.87 (d, 1H, *J* = 6.9 Hz), 3.83 (d, 1.2H, *J* = 6.9 Hz), 3.62–3.76 (m, 17.6H), 3.34–3.43 (m, 6.6H); ^{13}C NMR (75.5 MHz, DMSO-*d*₆) δ 165.66, 165.63, 158.1, 154.7, 154.6, 151.8, 151.5, 150.3, 150.2, 144.7, 143.7, 143.6, 143.5, 142.8, 141.3, 141.2, 140.6, 140.4, 140.3, 135.3, 135.2, 133.3, 132.4, 129.7, 128.8, 128.4, 127.9, 127.7, 127.6, 127.5, 127.2, 127.1, 126.9, 126.7, 125.4, 125.2, 125.1, 124.9, 124.6, 121.3, 119.98, 113.2, 88.9, 88.4, 85.4, 84.9, 84.7, 84.6, 72.5, 72.1, 66.8, 66.7, 63.9, 63.4, 60.6, 60.5, 55.0, 52.7, 52.6, 46.4, 45.9.

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-5-(pyren-1-yl)methyl-2-oxa-5-azabicyclo[2.2.1]heptane (18). Nucleoside 15 (225 mg, 0.33 mmol) was coevaporated with anhydrous 1,2-dichloroethane (2 × 5 mL) and redissolved in anhydrous 1,2-dichloroethane (4 mL). 1-Pyrenecarboxaldehyde (115 mg, 0.49 mmol) and NaBH(OAc)₃ (104 mg, 0.49 mmol) were added, and the resulting suspension was stirred at rt for 17 h, at which point sat. aq. NaHCO₃ (30 mL) was added. The mixture was extracted with CH₂Cl₂ (3 × 15 mL), and the combined organic layers were dried (Na₂SO₄) and evaporated to dryness. The resulting residue was purified by silica gel column chromatography (0–5% v/v MeOH in CH₂Cl₂) to afford N²-alkylated nucleoside 18 as a white foam (201 mg, 68%). *R*_f = 0.4 (EtOAc); MALDI-HRMS *m/z* 921.3326 ([M + Na]⁺, C₅₆H₄₆N₆O₆·Na⁺, calcd 921.3371); ^1H NMR³¹ (500 MHz, DMSO-*d*₆) δ 11.18 (s, 1H, ex, NH), 8.53 (s, 1H, H2), 8.46 (s, 1H, H8), 7.97–8.24 (m, 8H, Ar), 7.60–7.85 (m, 6H, Ar), 7.41–7.44 (m, 2H, DMTr), 7.19–7.32 (m, 7H, DMTr), 6.85–6.92 (m, 4H, DMTr), 6.50 (d, 1H, *J* = 1.9 Hz, H1'), 6.14 (d, 1H, ex, *J* = 3.6 Hz, 3'-OH), 4.72–4.75 (d, 1H, *J* = 12.5 Hz, CH₂Py), 4.60 (d, 1H, *J* = 3.6 Hz, H3'), 4.52–4.56 (d, 1H, *J* = 12.5 Hz, CH₂Py), 3.73 (s, 6H, CH₃O), 3.66 (s, 1H, H2'), 3.34–3.45 (m, 3H, 2 × H5', H5''), 3.17–3.20 (d, 1H, *J* = 10.3 Hz, H5''); ^{13}C NMR (125 MHz, DMSO-*d*₆) δ 165.6, 158.0, 151.7, 151.0 (C2), 149.9, 144.8,

142.8 (C8), 135.5, 135.4, 133.6, 133.2, 132.4 (Ar), 130.6, 130.2, 130.0, 129.71 (DMTr), 129.68 (DMTr), 128.7, 128.5 (Ar), 128.4 (Ar), 127.8 (DMTr), 127.7 (DMTr), 127.6 (Ar), 127.2 (Ar), 126.9 (Ar), 126.8 (Ar), 126.6 (DMTr), 125.9 (Ar), 125.5, 124.9 (Ar), 124.8 (Ar), 124.2 (Ar), 123.9, 123.7, 123.1 (Ar), 113.2 (DMTr), 90.3, 85.2, 84.8 (C1'), 75.4 (C3'), 66.3 (C2'), 61.3 (C5'), 59.2 (C5''), 58.2 (CH₂Py), 55.0 (CH₃O).

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-5-(pyren-1-yl)carbonyl-2-oxa-5-azabicyclo[2.2.1]heptane (19). Amino alcohol 15 (0.41 g, 0.59 mmol) was coevaporated with anhydrous 1,2-dichloroethane (2 × 10 mL) and dissolved in anhydrous CH₂Cl₂ (11.9 mL), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) (226 mg, 1.19 mmol) and 1-pyrenecarboxylic acid (0.29 g, 1.19 mmol) were added thereto. The reaction mixture was stirred for 45 h at rt, at which point it was diluted with CH₂Cl₂ (50 mL) and washed with water (20 mL). The two phases were separated, and the aqueous phase was back-extracted with CH₂Cl₂ (3 × 50 mL). The combined organic phases were evaporated to dryness, and the resulting residue was purified by silica gel column chromatography (0–99% v/v EtOAc and 1% v/v pyridine in petroleum ether). The resulting product was coevaporated with abs. EtOH:toluene (2 × 50 mL, 1:1 v/v) to afford nucleoside 19 (343 mg, 64%) as a yellow solid material. Physical data for the mixture of rotamers (~0.4:1 by ¹H NMR): *R*_f = 0.5 (5% v/v MeOH:CH₂Cl₂); MALDI-HRMS *m/z* 935.3138 ([M + Na]⁺, C₅₆H₄₄N₆O₇·Na⁺, calcd 935.3164). ¹H NMR^{31,32} (300 MHz, DMSO-*d*₆) δ 11.21 (br s, 1.4H, ex, NH), 8.55 (s, 1H, A^{Bz}_B), 8.53 (s, 0.4H, A^{Bz}_A), 8.45 (s, 1H, A^{Bz}_B), 8.40 (s, 0.4H, A^{Bz}_A), 6.82–8.23 (m, ~37.8H, Ar_{A+B}), 6.50 (d, 1H, *J* = 2.2 Hz, H1'_B), 6.40 (d, 0.4H, *J* = 1.8 Hz, H1'_A), 6.15 (d, 1H, ex, *J* = 4.0 Hz, 3'-OH_B), 6.07 (d, 0.4H, ex, *J* = 3.7 Hz, 3'-OH_A), 4.42–4.77 (m, 4.2H, H3'_{A+B}, HS'_{A+B}), 3.55–3.75 (m, ~9.8H, CH₂O_{A+B}, H2'_{A+B}), 3.15–3.44 (m, ~2.8H, HS''_{A+B}); ¹³C NMR (75.5 MHz, DMSO-*d*₆) δ 165.5, 157.9, 157.7, 151.7, 150.98, 149.8, 148.2, 144.7, 142.8, 140.1, 135.4, 135.3, 133.5, 133.1, 132.3, 130.5, 130.2, 129.9, 129.6, 128.8, 128.6, 128.4, 127.8, 127.6, 127.5, 127.3, 127.2, 126.9, 126.5, 126.3, 125.9, 125.5, 124.9, 124.8, 124.78, 124.2, 123.8, 123.7, 123.1, 113.1, 112.7, 92.0, 90.3, 85.1, 84.7, 79.8, 75.3, 74.7, 66.4, 61.2, 59.1, 58.6, 58.3, 58.2, 54.6.

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-5-(pyren-1-yl)acetyl-2-oxa-5-azabicyclo[2.2.1]heptane (20). Amino alcohol 15 (0.25 g, 0.37 mmol) was coevaporated with anhydrous 1,2-dichloroethane (2 × 5 mL) and dissolved in anhydrous CH₂Cl₂ (10 mL). To this was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) (108 mg, 0.55 mmol) and 1-pyreneacetic acid (145 mg, 0.55 mmol). The reaction mixture was stirred for 2.5 h at rt, at which point it was diluted with CH₂Cl₂ (20 mL) and washed with water (2 × 10 mL). The aqueous layer was back-extracted with CH₂Cl₂ (10 mL), and the combined organic layers were evaporated to dryness. The resulting crude residue was purified by silica gel column chromatography (0–4% v/v MeOH in CH₂Cl₂) to afford nucleoside 20 as a white solid (0.27 g, 79%). Physical data for the mixture of rotamers (~0.5:1.0 by ¹H NMR): *R*_f = 0.5 (10% v/v MeOH:CH₂Cl₂); MALDI-HRMS *m/z* 949.3321 ([M + Na]⁺, C₅₇H₄₆N₆O₇·Na⁺, calcd 949.3320); ¹H NMR^{31,32} (500 MHz, DMSO-*d*₆) δ 11.29 (br s, 1.5H, ex, NH_{A+B}), 8.97 (s, 1H, H8_B), 8.73 (s, 0.5H, H2_A), 8.71 (s, 1H, H2_B), 8.55 (s, 0.5H, H8_A), 6.91–8.32 (m, 40.5H, Ar_{A+B}), 6.83 (d, 0.5H, *J* = 1.7 Hz, H1'_A), 6.80 (d, 1H, *J* = 1.4 Hz, H1'_B), 6.32 (d, 0.5H, ex, *J* = 4.4 Hz, 3'-OH_A), 6.19 (d, 1H, ex, *J* = 4.4 Hz, 3'-OH_B), 5.07 (s, 0.5H, H2'_A), 4.71–4.73 (m, 1.5H, H2'_B, H3'_A), 4.67 (d, 1H, *J* = 10.4 Hz, HS'_B), 4.63 (d, 1H, *J* = 4.4 Hz, H3'_B), 4.55–4.60 (d, 1H, *J* = 17.0 Hz, CH₂Py_B), 4.36–4.40 (d, 1H, *J* = 17.0 Hz, CH₂Py_A), 4.11 (d, 0.5H, *J* = 16.2 Hz, CH₂Py_A), 3.96–4.03 (m, 1.5H, HS''_A, HS''_B), 3.66–3.77 (m, 9.5H, CH₃O, HS'_A), 3.34–3.48 (m, 3.5H, HS'_{A+B}, CH₂Py_A); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 169.9, 169.6, 165.6, 165.5, 158.1, 158.0, 152.0, 151.7 (A^{Bz}_A), 151.5, 151.4 (A^{Bz}_B), 150.6, 150.2, 144.71, 144.68, 141.7 (A^{Bz}_B), 141.5 (A^{Bz}_A), 135.4, 135.2, 133.54, 133.47, 132.5 (Ar), 130.70, 130.69, 130.28, 130.1, 129.91, 129.88, 129.82 (Ar), 129.79 (Ar), 129.77, 129.74 (Ar), 129.68, 129.62, 129.4, 129.2, 128.8, 128.7, 128.58 (Ar), 128.56 (Ar), 128.54 (Ar), 128.46 (Ar), 128.2 (Ar),

127.85 (Ar), 127.77 (Ar), 127.72 (Ar), 127.4 (Ar), 127.27 (Ar), 127.2 (Ar), 127.1 (Ar), 126.9, 126.8 (Ar), 126.68 (Ar), 126.2, 126.0 (Ar), 125.9 (Ar), 125.4, 125.3, 125.00 (Ar), 124.98 (Ar), 124.82 (Ar), 124.76 (Ar), 124.7 (Ar), 124.6 (Ar), 124.5 (Ar), 124.4 (Ar), 124.3 (Ar), 124.1, 123.89, 123.79, 123.76, 123.72, 123.2 (Ar), 113.2 (Ar), 89.0, 88.4, 85.5, 85.4, 84.73 (C1'_A), 84.66 (C1'_B), 72.9 (C3'_A), 72.0 (C3'_B), 64.5 (C2'_A), 61.8 (C2'_B), 60.9 (C5'_B), 60.8 (C5'_A), 55.0 (CH₃O), 52.8 (C5''_B), 52.3 (C5''_A), 37.8 (CH₂Py_B), 37.7 (CH₂Py_A). Trace impurities of dichloromethane and 1-pyreneacetic acid were identified in the ¹³C NMR spectrum. The compound was used in the next step without further purification.

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-7-[2-cyanoethoxy-diisopropylamino]phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-5-(9''-fluorenylmethoxycarbonyl)-2-oxa-5-azabicyclo[2.2.1]heptane (1). Nucleoside 17 (225 mg, 0.25 mmol) was coevaporated with anhydrous 1,2-dichloroethane (2 × 4 mL) and redissolved in anhydrous CH₂Cl₂ (3.5 mL). Anhydrous *N,N'*-diisopropylethylamine (DIPEA) (195 μL, 1.12 mmol) and *N*-methylimidazole (NMI) (16 μL, 0.20 mmol) were added, followed by dropwise addition of 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite (111 μL, 0.50 mmol). The reaction mixture was stirred for 4 h at rt and evaporated to dryness, and the resulting residue was purified by silica gel column chromatography (0–2% v/v MeOH in CH₂Cl₂ v/v, initially built in 0.5% v/v Et₃N) and subsequent precipitation from CH₂Cl₂/petroleum ether to afford target amidite 1 (126 mg, 46%) as a white foam. Physical data for mixture of rotamers: *R*_f = 0.5 (5% v/v MeOH in CH₂Cl₂); ESI-HRMS *m/z* 1129.4356 ([M + Na]⁺, C₆₃H₆₃N₈O₉P·Na⁺, calcd 1129.4348); ³¹P NMR (121 MHz, CDCl₃) δ 150.32, 150.26, 150.1, 149.5.

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-7-[2-cyanoethoxy-diisopropylamino]phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-5-(pyren-1-yl)methyl-2-oxa-5-azabicyclo[2.2.1]heptane (2). Nucleoside 18 (155 mg, 0.17 mmol) was coevaporated with 1,2-dichloroethane (2 × 5 mL) and dissolved in a 20% v/v *N,N'*-diisopropylethylamine solution in anhydrous CH₂Cl₂ (5.0 mL). To this was added 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite (0.10 mL, 0.44 mmol), and the reaction mixture was stirred at rt for 17 h, whereupon the reaction was quenched with abs EtOH (1 mL) and the mixture was evaporated to dryness. The resulting residue was purified by silica gel column chromatography (0–90% v/v EtOAc in petroleum ether) and precipitated from CH₂Cl₂/petroleum ether to afford amidite 2 as a white solid material (131 mg, 69%). *R*_f = 0.7 (5% v/v MeOH in CH₂Cl₂); ESI-HRMS *m/z* 1099.4642 ([M + H]⁺, C₆₅H₆₃N₈O₇P·H⁺, calcd 1099.4630); ³¹P NMR (121 MHz, CDCl₃) δ 150.6, 148.4.

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-7-[2-cyanoethoxy-diisopropylamino]phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-5-(pyren-1-yl)carbonyl-2-oxa-5-azabicyclo[2.2.1]heptane (3). Nucleoside 19 (0.30 g, 0.33 mmol) was coevaporated with 1,2-dichloroethane (2 × 5 mL) and dissolved in 20% v/v *N,N'*-diisopropylethylamine in anhydrous CH₂Cl₂ (3.4 mL). To this was added 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite (0.11 mL, 0.49 mmol), and the reaction mixture was stirred for 22 h at rt, at which point abs. EtOH (2 mL) was added. The mixture was taken up in CH₂Cl₂ (50 mL) and washed with sat. aq. NaHCO₃ (50 mL) and brine (50 mL). The combined aqueous layers were back-extracted with CH₂Cl₂ (2 × 20 mL), and the combined organic layers were evaporated to dryness. The resulting residue was purified by silica gel column chromatography (0–99% v/v EtOAc in petroleum ether containing 1% v/v pyridine), coevaporated with abs. EtOH:toluene (2 × 50 mL, 1:1 v/v), and precipitated from EtOAc/hexane to afford phosphoramidite 3 as a white foam (247 mg, 67%). Physical data for the mixture of rotamers: *R*_f = 0.5 (EtOAc); ESI-HRMS *m/z* 1113.4462 ([M + H]⁺, C₆₅H₆₁N₈O₈P·H⁺, calcd 1113.4422); ³¹P NMR (121 MHz, CDCl₃) δ 152.3, 151.8, 150.2.

(1S,3R,4S,7R)-3-(6-N-Benzoyladenine-9-yl)-7-[2-cyanoethoxy-diisopropylamino]phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-5-(pyren-1-yl)acetyl-2-oxa-5-azabicyclo[2.2.1]heptane (4). Nucleoside 20 (235 mg, 0.25 mmol) was coevaporated with anhydrous 1,2-dichloroethane (2 × 5 mL) and redissolved in anhydrous CH₂Cl₂ (5 mL). Anhydrous *N,N'*-diisopropylethylamine

(220 μL , 1.27 mmol) was added, followed by dropwise addition of 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite (115 μL , 0.51 mmol). The reaction mixture was stirred at rt for 22 h, at which point abs. EtOH (1 mL) was added. The solution was evaporated to dryness, and the resulting crude residue was purified by silica gel column chromatography (0–2% v/v MeOH in CH_2Cl_2) and precipitation from CH_2Cl_2 /petroleum ether to afford target amidite 4 (203 mg, 71%) as a white foam. Physical data for the mixture of rotamers: $R_f = 0.6$ (5% v/v MeOH in CH_2Cl_2); MALDI-HRMS m/z 1149.4358 ($[\text{M} + \text{Na}]^+$, $\text{C}_{66}\text{H}_{63}\text{N}_8\text{O}_8\text{P}\cdot\text{Na}^+$, calcd 1149.4399); ^{31}P NMR (121 MHz, CDCl_3) δ 150.4, 150.31, 150.26, 148.1.

Synthesis of ONs. W/X/Y/Z-modified oligodeoxyribonucleotides were made on an automated DNA synthesizer using 0.2 μmol scale succinyl-linked long-chain alkylamine controlled pore glass (LCAA-CPG) columns with a pore size of 500 Å. Phosphoramidites 1–4 were incorporated into ONs using the following hand-coupling conditions (activator; coupling time; stepwise coupling yield): monomer W (pyridinium hydrochloride; 30 min; ~82%); monomers X–Z (pyridinium hydrochloride; 15 min; ~95%). Standard protocols for incorporation of DNA phosphoramidites were used. Modified ONs were deprotected using 32% aq. NH_3 (55 °C, 2–12 h) and purified (DMTr-ON) by ion-pair reversed-phase HPLC using either an ammonium formate/acetonitrile gradient or a triethylammonium acetate/acetonitrile gradient, which was followed by detritylation (80% aq. AcOH, 20 min) and precipitation (abs. EtOH or acetone, –18 °C, 12 h). The compositions of the modified ONs were verified by MALDI-MS analysis (Tables S1 and S2 in the Supporting Information) recorded in either positive or negative ion mode on a quadrupole time-of-flight tandem mass spectrometer equipped with a MALDI source using 3-hydroxypicolinic acid as a matrix. Purity (>90% unless stated otherwise) was verified either by the ion-pair reversed-phase HPLC system running in analytical mode or ion-exchange HPLC using a Tris-Cl/EDTA–NaCl gradient.

Protocol for Thermal Denaturation Studies. Concentrations of ONs were calculated using the following extinction coefficients ($\text{OD}_{260}/\mu\text{mol}$): G, 12.0; A, 15.2; T, 8.4; U, 10.0; C, 7.1; pyrene, 22.4. ONs (each strand at 1.0 μM) were thoroughly mixed, denatured by heating, and subsequently cooled to the starting temperature of the experiment. Quartz optical cells with a path length of 10.0 mm were used. The thermal denaturation temperature ($T_m/^\circ\text{C}$) was measured on a temperature-controlled UV–vis spectrophotometer and determined as the maximum of the first derivative of the thermal denaturation curve (A_{260} vs T) recorded in medium-salt buffer (T_m buffer) (100 mM NaCl, 0.1 mM EDTA, and pH 7.0 adjusted with 10 mM $\text{NaH}_2\text{PO}_4/5$ mM Na_2HPO_4). The temperature of the denaturation experiments ranged from at least 15 °C below T_m to 20 °C above T_m (although not below 3 °C). A temperature ramp of 0.5 °C/min or 1.0 °C/min was used in the experiments. The reported thermal denaturation temperatures are averages of two measurements within ± 1.0 °C.

Protocol for UV–Vis Absorption Spectroscopy. UV–vis spectra were recorded on a spectrophotometer at 5 °C (except for single-stranded X/Y-modified probes, which were recorded at room temperature) using each strand at a concentration of 1 μM in T_m buffer and quartz cells with 1 cm path lengths.

Protocol for Fluorescence Emission Spectroscopy. Steady-state fluorescence spectra were recorded at 5 °C using an excitation wavelength of $\lambda_{\text{ex}} = 350$ nm, each strand at 1 μM concentration in T_m buffer (except with Y-modified ONs, where strands were used at 0.15 μM concentration), and quartz cells with 1 cm path lengths.

■ ASSOCIATED CONTENT

■ Supporting Information

General experimental section; additional synthetic strategies; NMR spectra for all new compounds; MS data for all modified ONs; representative thermal denaturation curves; additional T_m data; representative absorption and fluorescence emission spectra; and evaluation of SNP-discriminatory potential. This

material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: hrdlicka@uidaho.edu.

Author Contributions

[§]N.K.A. and B.A.A. contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

P.J.H. appreciates financial support through Award R01 GM088697 from the National Institute of General Medical Sciences, National Institutes of Health, and from the Institute of Translational Health Sciences (ITHS) (supported by Grants UL1 RR025014, KL2 RR025015, and TL1 RR025016 from the National Center for Research Resources, NIH). J.W. appreciates financial support from The Danish National Research Foundation and the Danish Agency for Science Technology and Innovation. We thank Dr. T. Santhosh Kumar (University of Southern Denmark) for providing us with starting material and Dr. Lee Deobald (EBI Murdock Mass Spectrometry Center, University of Idaho) for mass spectrometric analyses.

■ REFERENCES

- (1) For reviews of conformationally restricted nucleotides, see, for example: (a) Leumann, C. J. *Bioorg. Med. Chem.* **2002**, *10*, 841–854. (b) Obika, S.; Abdur Rahman, S. M.; Fujisaka, A.; Kawada, Y.; Baba, T.; Imanishi, T. *Heterocycles* **2010**, *81*, 1347–1392. (c) Prakash, T. P. *Chem. Biodiversity* **2011**, *8*, 1616–1641. (d) Deleavey, G. F.; Damha, M. J. *Chem. Biol.* **2012**, *19*, 937–954. (e) Zhou, C.; Chattopadhyaya, J. *Chem. Rev.* **2012**, *112*, 3808–3832.
- (2) (a) Duca, M.; Vekhoff, P.; Oussedik, K.; Halby, L.; Arimondo, P. B. *Nucleic Acids Res.* **2008**, *36*, 5123–5138. (b) Bennett, C. F.; Swayze, E. E. *Annu. Rev. Pharmacol. Toxicol.* **2010**, *50*, 259–293. (c) Østergaard, M. E.; Hrdlicka, P. J. *Chem. Soc. Rev.* **2011**, *40*, 5771–5788. (d) Watts, J. K.; Corey, D. R. *J. Pathol.* **2012**, *226*, 365–379. (e) Matsui, M.; Corey, D. R. *Drug Discovery Today* **2012**, *17*, 443–450. (f) Dong, H.; Lei, J.; Ding, L.; Wen, Y.; Ju, H.; Zhang, X. *Chem. Rev.* **2013**, *113*, 6207–6233.
- (3) Singh, S. K.; Nielsen, P.; Koshkin, A. A.; Wengel, J. *Chem. Commun.* **1998**, 455–456.
- (4) Obika, S.; Nanbu, D.; Hari, Y.; Andoh, J.-I.; Morio, K.-I.; Doi, T.; Imanishi, T. *Tetrahedron Lett.* **1998**, *39*, 5401–5404.
- (5) Kaur, H.; Babu, B. R.; Maiti, S. *Chem. Rev.* **2007**, *107*, 4672–4697.
- (6) (a) Rajwanshi, V. K.; Håkansson, A. E.; Dahl, B. M.; Wengel, J. *Chem. Commun.* **1999**, 1395–1396. (b) Sørensen, M. D.; Kværnø, L.; Bryld, T.; Håkansson, A. E.; Verbeure, B.; Gaubert, G.; Herdewijn, P.; Wengel, J. *J. Am. Chem. Soc.* **2002**, *124*, 2164–2176.
- (7) Recent examples include: (a) Seth, P. P.; Vasquez, G.; Allerson, C. A.; Berdeja, A.; Gaus, H.; Kinberger, G. A.; Prakash, T. P.; Migawa, M. T.; Bhat, B.; Swayze, E. E. *J. Org. Chem.* **2010**, *75*, 1569–1581. (b) Li, Q.; Yuan, F.; Zhou, C.; Plashkevych, O.; Chattopadhyaya, J. *J. Org. Chem.* **2010**, *75*, 6122–6140. (c) Liu, Y.; Xu, J.; Karimiahmadabadi, M.; Zhou, C.; Chattopadhyaya, J. *J. Org. Chem.* **2010**, *75*, 7112–7128. (d) Upadhyaya, R.; Deshpande, S. A.; Li, Q.; Kardile, R. A.; Sayyed, A. Y.; Kshirsagar, E. K.; Salunke, R. V.; Dixit, S. S.; Zhou, C.; Foldesi, A.; Chattopadhyaya, J. *J. Org. Chem.* **2011**, *76*, 4408–4431. (e) Shrestha, A. R.; Hari, Y.; Yahara, A.; Osawa, T.; Obika, S. *J. Org. Chem.* **2011**, *76*, 9891–9899. (f) Hanessian, S.; Schroeder, B. R.; Giacometti, R. D.; Merner, B. L.; Østergaard, M. E.; Swayze, E. E.; Seth, P. P. *Angew. Chem., Int. Ed.* **2012**, *51*, 11242–11245. (g) Haziri, A. I.; Leumann, C. J. *J. Org. Chem.* **2012**, *77*, 5861–

5869. (h) Gerber, A.-B.; Leumann, C. J. *Chem.—Eur. J.* **2013**, *19*, 6990–7006. (i) Morihito, K.; Kodama, T.; Kentefu; Moai, Y.; Veedu, R. N.; Obika, S. *Angew. Chem., Int. Ed.* **2013**, *52*, 5074–5078. (j) Hari, Y.; Osawa, T.; Kotobuki, Y.; Yahara, A.; Shrestha, A. R.; Obika, S. *Bioorg. Med. Chem.* **2013**, *21*, 4405–4412. (k) Hari, Y.; Morikawa, T.; Osawa, T.; Obika, S. *Org. Lett.* **2013**, *15*, 3702–3705. (l) Migawa, M. T.; Prakash, T. P.; Vasquez, G.; Seth, P. P.; Swayze, E. E. *Org. Lett.* **2013**, *15*, 4316–4319. (m) Hanessian, S.; Schroeder, B. R.; Merner, B. L.; Chen, B.; Swayze, E. E.; Seth, P. P. *J. Org. Chem.* **2013**, *78*, 9051–9063. (n) Hanessian, S.; Waggoner, J.; Merner, B. L.; Giacometti, R. D.; Østergaard, M. E.; Swayze, E. E.; Seth, P. P. *J. Org. Chem.* **2013**, *78*, 9064–9075.
- (8) For recent examples, see: (a) Karmakar, S.; Anderson, B. A.; Rathje, R. L.; Andersen, S.; Jensen, T.; Nielsen, P.; Hrdlicka, P. J. *J. Org. Chem.* **2011**, *76*, 7119–7131. (b) Didion, B. A.; Karmakar, S.; Guenther, D. C.; Sau, S.; Versteegen, J. P.; Hrdlicka, P. J. *ChemBioChem* **2013**, *14*, 1534–1538. (c) Denn, B.; Karmakar, S.; Guenther, D. C.; Hrdlicka, P. J. *Chem. Commun.* **2013**, *49*, 9851–9853.
- (9) (a) Kumar, T. S.; Madsen, A. S.; Wengel, J.; Hrdlicka, P. J. *J. Org. Chem.* **2006**, *71*, 4188–4201. (b) Kumar, T. S.; Madsen, A. S.; Østergaard, M. E.; Sau, S. P.; Wengel, J.; Hrdlicka, P. J. *J. Org. Chem.* **2009**, *74*, 1070–1081.
- (10) Kumar, T. S.; Wengel, J.; Hrdlicka, P. J. *ChemBioChem* **2007**, *8*, 1122–1125.
- (11) Kumar, T. S.; Madsen, A. S.; Østergaard, M. E.; Wengel, J.; Hrdlicka, P. J. *J. Org. Chem.* **2008**, *73*, 7060–7066.
- (12) (a) Sau, S. P.; Kumar, T. S.; Hrdlicka, P. J. *Org. Biomol. Chem.* **2010**, *8*, 2028–2036. (b) Sau, S. P.; Madsen, A. S.; Podbevsek, P.; Andersen, N. K.; Kumar, T. S.; Andersen, S.; Rathje, R. L.; Anderson, B. A.; Guenther, D. C.; Karmakar, S.; Kumar, P.; Plavec, J.; Wengel, J.; Hrdlicka, P. J. *J. Org. Chem.* **2013**, *78*, 9560–9570.
- (13) A conference proceeding outlining a portion of this study has been published. See: Andersen, N. K.; Wengel, J.; Hrdlicka, P. J. *Nucleosides, Nucleotides Nucleic Acids* **2007**, *26*, 1415–1417.
- (14) Wenska, M.; Honcharenko, D.; Pathmasiri, W.; Chattopadhyaya, J. *Heterocycles* **2007**, *73*, 303–324.
- (15) Rosenbohm, C.; Christensen, S. M.; Sørensen, M. D.; Pedersen, D. S.; Larsen, L.-E.; Wengel, J.; Koch, T. *Org. Biomol. Chem.* **2003**, *1*, 655–663.
- (16) Hrdlicka, P. J.; Andersen, N. K.; Jepsen, J. S.; Hansen, F. G.; Haselmann, K. F.; Nielsen, C.; Wengel, J. *Bioorg. Med. Chem.* **2005**, *77*, 2597–2621.
- (17) (a) Ellervik, U.; Magnusson, G. *Tetrahedron Lett.* **1997**, *38*, 1627–1628. (b) Rigoli, J. W.; Østergaard, M. E.; Canady, K. M.; Guenther, D. C.; Hrdlicka, P. J. *Tetrahedron Lett.* **2009**, *50*, 1751–1753.
- (18) The conversion of **7** into **9** has been outlined in the patent literature. See: Sørensen, M. D.; Wengel, J.; Koch, T.; Christensen, S. M.; Rosenbohm, C.; Pedersen, D. S. WO 2003095467 A1.
- (19) Takaku, H.; Morita, K.; Sumiuchi, T. *Chem. Lett.* **1983**, 1661–1664.
- (20) The signal for H3' appears as a doublet in nucleosides with unmodified 3'-OH groups.
- (21) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. *J. Org. Chem.* **1996**, *61*, 3849–3862.
- (22) Hakånsson, A. E.; Wengel, J. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 935–938.
- (23) Crothers, D. M. *Biopolymers* **1968**, *6*, 575–584.
- (24) (a) Yamana, K.; Iwase, R.; Furutani, S.; Tsuchida, H.; Zako, H.; Yamaoka, T.; Murakami, A. *Nucleic Acids Res.* **1999**, *27*, 2387–2392. (b) Christensen, U. B.; Pedersen, E. B. *Nucleic Acids Res.* **2002**, *30*, 4918–4925. (c) Bryld, T.; Højland, T.; Wengel, J. *Chem. Commun.* **2004**, 1064–1065.
- (25) Marin, V.; Hansen, H. F.; Koch, T. R.; Armitage, B. A. *J. Biomol. Struct. Dyn.* **2004**, *21*, 841–850.
- (26) (a) Korshun, V. A.; Stetsenko, D. A.; Gait, M. J. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1092–1104. (b) Dohno, C.; Saito, I. *ChemBioChem* **2005**, *6*, 1075–1081.
- (27) (a) Dougherty, G.; Pilbrow, J. R. *Int. J. Biochem.* **1984**, *16*, 1179–1192. (b) Nakamura, M.; Fukunaga, Y.; Sasa, K.; Ohtoshi, Y.; Kanaori, K.; Hayashi, H.; Nakano, H.; Yamana, K. *Nucleic Acids Res.* **2005**, *33*, 5887–5895. (c) Asanuma, H.; Fujii, T.; Kato, T.; Kashida, H. *J. Photochem. Photobiol., C* **2012**, *13*, 124–135.
- (28) (a) Okamoto, A.; Kanatani, K.; Saito, I. *J. Am. Chem. Soc.* **2004**, *126*, 4820–4827. (b) Østergaard, M. E.; Kumar, P.; Baral, B.; Guenther, D. C.; Anderson, B. A.; Ytreberg, F. M.; Deobald, L.; Paszczynski, A. J.; Sharma, P. K.; Hrdlicka, P. J. *Chem.—Eur. J.* **2011**, *17*, 3157–3165.
- (29) Manoharan, M.; Tivel, K. L.; Zhao, M.; Nafisi, K.; Netzel, T. L. *J. Phys. Chem.* **1995**, *99*, 17461–17472. (b) Seo, Y. J.; Ryu, J. H.; Kim, B. H. *Org. Lett.* **2005**, *7*, 4931–4933.
- (30) Persil, O.; Hud, N. V. *Trends Biotechnol.* **2007**, *25*, 433–436.
- (31) The assignments of the ¹H NMR signals (and of the corresponding ¹³C signals) of HS', HS'', and CH₂Ph (if present) are interchangeable.
- (32) The least predominant rotamer is denoted as "A".